Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2.
Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G, et al.
Walpole ET, et al. Among authors: dutcher jp.
J Immunother Emphasis Tumor Immunol. 1993 May 4;13(4):275-81. doi: 10.1097/00002371-199305000-00007.
J Immunother Emphasis Tumor Immunol. 1993.
PMID: 8101452
Clinical Trial.